Podcast Summary: Diabetes Core Update

Special Edition – Oral GLP-1 Receptor Agonist

Release Date: February 11, 2026
Host: Dr. Neal Skolnick
Guest: Dr. W. Timothy Garvey

Episode Overview

This special episode of Diabetes Core Update focuses on the recent FDA approval and clinical implications of oral GLP-1 receptor agonists, specifically oral semaglutide, for obesity management. Host Dr. Neal Skolnick is joined by leading expert Dr. W. Timothy Garvey to discuss the science behind the oral formulation, pivotal clinical trial findings, metabolic and functional outcomes, safety, practical prescribing considerations, and broader implications for patients and clinicians.

Key Discussion Points and Insights

1. Background: Evolution of GLP-1 Agonists

• Injectable Roots:

  • GLP-1 agonists, since exenatide’s introduction in the early 2000s, started as injectables due to their peptide structure, which gets digested if taken orally ([03:10]).
  • Modifications have enabled long-acting, weekly injectable options.

• Innovation in Delivery:

  • Development of oral formulations required advanced pharmaceutical engineering to prevent digestive breakdown; specifically, semaglutide is delivered with SNAC (an absorption enhancer), enabling about 1.5–3% oral bioavailability ([04:35]).

  “It was a whole nother ball game in terms of bringing this into an oral formulation... It prevented digestion of the protein in the stomach and altered pH locally to allow absorption.”
  —Dr. Garvey, [04:35]

2. Clinical Trial Findings: Efficacy and Key Outcomes

• OASIS Trials (OASIS 1 and 4):

  • OASIS 1:
    • Max dose: 50mg daily
    • Result: ~15.1% weight loss (intent-to-treat analysis) ([06:24])
  • OASIS 4:
    • Max dose: 25mg daily—pursued for FDA approval
    • Result: ~13.6% weight loss (intent-to-treat); >16% in completer’s analysis ([07:13])
  • Clinical Importance:
    • These results place oral semaglutide in the “second generation” of obesity medications, delivering efficacy for both weight and health outcomes.

  “This level of efficacy for weight loss really gives us a tool to improve quality of life and to prevent and treat the complications...”
  —Dr. Garvey, [06:24]

• Metabolic Outcomes:

  • Both OASIS trials included patients without diabetes.
  • Key Findings ([08:43]):
    • HbA1c ↓ 0.3%
    • Fasting glucose ↓ ~6 mg/dL
    • Fasting insulin ↓ 25–30% — indicative of improved insulin sensitivity.
    • Triglycerides and C-reactive protein decreased.
    • No significant difference in BP compared to placebo in OASIS 4, which was unexpected.
    • Prediabetes reversal: 70–75% to normoglycemia.
  • Physical Function:
    • No decline in muscle function (sit-to-stand test); improved quality of life scores ([10:54]).
    • Body composition shifts: ~⅓ lean mass loss, ~⅔ fat loss, especially visceral fat.

3. Safety and Side Effects

• GI Effects:

  • Similar to injectables:
    • Nausea (40–45%)
    • Vomiting (~30%)
    • Diarrhea/constipation (~20%)
  • Mainly during dose escalation; mostly mild/moderate and rarely leading to discontinuation ([14:30]).
  • Mechanism: Appetite and nausea are mediated by GLP-1 receptors in different areas of the brain.

  “The oral preparation does not get around these GI side effects... a 40–45% prevalence of nausea, 30% vomiting...”
  —Dr. Garvey, [14:30]

• Unique Adverse Event – Dysesthesias:

  • Reported in ~5% of patients; higher with higher doses ([15:40]).
  • Symptoms: tingling, altered sensation, rarely painful.
  • Generally resolve with dose reduction or discontinuation.

  “[Dysesthesias] can be tingly, it can even have some painful characteristics to it...”
  —Dr. Garvey, [15:40]

4. Cardiovascular Safety and Efficacy

• SELECT Study (injectable semaglutide):

  • 17,600 patients with obesity (no diabetes)
  • 20% reduction in major adverse cardiovascular events (MACE) over four years ([17:18]).
  • FDA labeling for oral semaglutide carries forward secondary prevention indication for CVD.

• Clinical Implication:

  • Oral GLP-1’s oral form may lower barriers, especially for patients under cardiovascular specialists less familiar with injectables.

  “This indication for secondary prevention... was carried over to apply to oral semaglutide. So the oral semaglutide 25mg also has... FDA approved indication for cardiovascular disease prevention.”
  —Dr. Garvey, [18:15]

• Debate on Risk Stratification:

  • Dr. Skolnick raises considering GLP-1 use in those with high coronary artery calcium scores even without an event ([20:18]).
  • Dr. Garvey agrees: strong rationale to use GLP-1s to mitigate risk in high-risk (even pre-event) populations ([21:29]).

5. Practical Prescribing Considerations

• Dosing:

  • Titration required over several months:
    • Start at 1.45mg daily for a month, then escalate to 4mg, then 9mg, finally 25mg ([22:31]).
  • 25mg is the dose FDA-approved for obesity.
  • Only 30-day supplies per dose—may need dual prescriptions to slow titration for individual tolerance.

• Administration:

  • Take in the morning, fasting, with ~4oz water.
  • Wait 30–60 minutes before any food, drink (including coffee). Adherence impacts efficacy ([23:05]).

  “With the oral preparation, because of the SNAC matrix... you need to take these oral semaglutide in the morning before... anything to eat with a half a cup of water... not eat anything for the next 30 to 60 minutes.”
  —Dr. Garvey, [23:05]

• Switching from Injectable to Oral:

  • No direct equivalency data.
  • Wait at least a week after last injection before starting oral.
  • If tolerating max injectable (2.4mg), move to 25mg oral; use judgment and go lower if GI side effects are present ([24:51]).
  • Conservative approach— not a race to maximum dose.

  “It's... not a race here to get patients up to the maximal dose... always better to be more conservative, I think. Take your time.”
  —Dr. Garvey, [25:52]

6. Accessibility and Adherence

• Global Impact:

  • Oral formulations do not need refrigeration — a significant advantage for distribution worldwide and patient convenience during travel ([26:31]).

  “The advantage of the orals is they don't need to be refrigerated... for worldwide distribution and accessibility, this is a very good thing.”
  —Dr. Garvey, [26:46]

• Adherence Hope:

  • Higher preference for oral medication may improve long-term use and persistence, addressing a major challenge seen with current GLP-1 therapies ([27:30]).

  “If patients prefer oral medications... they’re more likely to be adherent... Maybe this will enhance adherence over a longer period of time.”
  —Dr. Garvey, [27:47]

Notable Quotes & Memorable Moments

• Drug Development Remark:
  • “It’s fascinating... to hear how that basic science moved along gives us a better appreciation of what goes into the medicines we use every day.”
    —Dr. Skolnick, [05:57]
• Safety Watch Out:
  • “You're pushing a button of mine when it comes to online availability of these prescriptions without evaluation by a healthcare professional.”
    —Dr. Garvey, [14:09]
• Global Perspective:
  • “The advantage of the orals is they don't need to be refrigerated... even for our patients in America, here for travel, it can just... make it easier to store and travel with the medicine.”
    —Dr. Garvey, [26:46]

Timestamps for Important Segments

• [03:10] – Peptide structure and why early GLP-1s were injectables
• [04:35] – The science and innovation behind the oral semaglutide formulation
• [06:24] – OASIS trial overview and weight loss efficacy
• [08:43] – Metabolic endpoints (A1c, insulin, prediabetes conversion)
• [10:54] – Physical function and composition findings
• [14:30] – GI side effects profile of oral semaglutide
• [15:40] – Dysesthesias: a possible new adverse effect
• [17:18] – Cardiovascular outcomes data and its application to oral semaglutide
• [22:31] – Practical prescribing: dosing, titration, insurance
• [23:05] – Administration specifics: timing, fasting, water requirements
• [24:51] – Switching from injectable to oral: practical approach
• [26:31] – Oral formulation’s global and travel advantages

Takeaways for Clinicians

• Oral semaglutide offers efficacy comparable to injectables for weight loss and metabolic outcomes, now with easier administration and likely broader patient uptake.
• Side effects and monitoring needs are similar to injectables; dose titration and GI tolerability remain pivotal.
• The cardiovascular prevention label extends to oral semaglutide, and experts foresee expanding indications, particularly in high-risk but pre-event patients.
• Proper clinician oversight, patient education, and gradual up-titration are essential for clinical success.
• The oral option may improve long-term treatment adherence and offers practical advantages, especially in resource-limited or travel-heavy settings.

This episode delivers a nuanced, evidence-based look at the new era of oral GLP-1 agonists for obesity—including how and why to prescribe them, safety caveats, and their future impact.